gastrointestinal%20stromal%20tumor
GASTROINTESTINAL STROMAL TUMOR
Gastrointestinal stromal tumors are morphologically spindle cell, epithelioid, or occasionally pleomorphic mesenchymal tumors of the gastrointestinal tract.
Signs and symptoms of gastrointestinal tumor include presence of abdominal mass (which may be an incidental finding in endoscopy), gastrointestinal bleeding, hemoperitoneum, anemia and gastrointestinal perforation.

Gastrointestinal%20stromal%20tumor Treatment

Principles of Therapy

Prior to Therapy

  • Assess present disease state for treatment monitoring purpose
  • Inform & discuss w/ patient that the tumor cannot be cured, the duration of treatment required by the condition including the course of possible disease progression
  • Determine the cardiac status
    • Physical activity should not be severely limited
    • No myocardial infarction within the last 2 months
  • Laboratory tests [eg liver function tests, complete blood count (CBC), etc]

Pharmacotherapy

Chemotherapy

Imatinib

  • Recommended treatment for gastrointestinal stromal tumor (GIST) that is unresectable &/or metastatic
    • Adjuvant therapy for patients w/ high risk of relapse & for ruptured tumor during surgery
  • Increases survival rate in patients w/ metastatic &/or unresectable GIST
  • When Imatinib is used pre-operative, positron emission tomography (PET) scan should be used to assess response

Discontinuation of Treatment

  • Stop Imatinib if intolerable side effects occur & restart once toxicity resolves
  • For less severe toxicity, consider decreasing the dose

Sunitinib

  • A 2nd-line agent that may be used if intolerance to Imatinib develops, if tumor is Imatinib resistant, or disease progression occurs
  • Demonstrated efficacy in terms of progression-free survival on a “4 weeks on-2 weeks off” regimen

Regorafenib

  • A 3rd-line agent for patients unresponsive to both Imatinib & Sunitinib
  • Shown to prolong progression-free survival in a prospective placebo-controlled randomized trial
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Yesterday
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 5 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).